Summary
The iron compound oxyferriscorbone® has been used as novel medication in more than 100 Parkinson patients. In 66% of the patients a beneficial clinical effect was observed 22% of the patients showed a very good (better than 30%) improvement of disability, 44% a moderate (up to 30%) improvement. The effect of iron was dependent on the dosage and the severity of the case but independent of the mode of application (i.v. or i.m.). The action of the iron medication lasts from 24 hours up to 4 days depending on the severity of the case.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Birkmayer W, Hornykiewicz O (1961) Der L-Dioxyphenylalanin-L-DOPA-Effekt bei der Parkinson-Akinese. Wien Klin Wochenschr 73: 787
Birkmayer W (1969) Der Alpha-methyl-p-Tyrosin-Effekt bei extrapyramidalen Erkrankungen. Wien Klin Wochenschr 81: 10
Birkmayer W, Neumayer E (1972) Die moderne medikamentöse Behandlung des Parkinsonismus. Z Neurol 202: 257
Birkmayer W, Riederer P (1985) Die Parkinson-Krankheit. Springer, Wien New York
Birkmayer W, Birkmayer JD (1986) Iron—a new aid in the treatment of Parkinson patients. J Neural Transm 67: 287
Birkmayer JD, Birkmayer W (1987) Improvement of disability and akinesia of patients with Parkinson’s disease by intravenous iron substitution. Ann Clin Sci 17: 32
Iliceto G, DeMari M, Federico F, et al (1987) Iron in Parkinson’s disease: preliminary report. Ital J Neurol Sci [Suppl] 7: 62
McGeer PL, McGeer EG, Wada JA (1971) Distribution of tyrosine hydroxylase in human and animal brain. J Neurochem 18: 1647
Nagatsu T, Oka K, Yamamoto T et al (1981) Catecholaminergic enzymes in Parkinson’s disease and related extrapyramidal diseases. In: Riederer P, Usdin E (eds) Transmitter biochemistry of human brain tissue. Macmillan, London, p 291
Nagatsu T, Oka K, Yamamoto T et al (1981) Catecholaminergic enzymes in Parkinson’s disease and related extrapyramidal diseases. In: Riederer P, Usdin E (eds) Transmitter biochemistry of human brain tissue. Macmillan, London, p 291
Rausch WD, Hirata Y, Nagatsu T, et al (1988) Tyrosine hydroxylase activity in caudate nucleus from Parkinson’s disease: effect of iron and phosphorylating agents. J Neurochem 50: 202–208
Rutledge JN, Hilal SK et al (1987) Study of movement disorders and brain iron by MR. AJNR 8: 397–411
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Springer-Verlag/Wien
About this paper
Cite this paper
Birkmayer, W., Birkmayer, J.G.D. (1989). Iron therapy in Parkinson’s disease. In: Przuntek, H., Riederer, P. (eds) Early Diagnosis and Preventive Therapy in Parkinson’s Disease. Key Topics in Brain Research. Springer, Vienna. https://doi.org/10.1007/978-3-7091-8994-8_37
Download citation
DOI: https://doi.org/10.1007/978-3-7091-8994-8_37
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-82080-3
Online ISBN: 978-3-7091-8994-8
eBook Packages: Springer Book Archive